Summary The potent kinase inhibitor staurosporine and its protein kinase C (PKC)-selective analogue CGP 41251 are known to sensitise cells with the multidrug resistance (MDR) phenotype mediated by Pglycoprotein (P-gp) to cytotoxic agents. Here four PKC-selective staurosporine cogeners, CGP 41251, UCN-01, RO 31 8220 and GF 109203X, were compared with staurosporine in terms of their MDR-reversing properties and their susceptibility towards P-gp-mediated drug efflux from MCF-7/Adr cells. Staurosporine was the most potent and the bisindolylmaleimides RO 31 8220 and GF 109203X the least potent cytostatic agents. When compared with MCF-7 wild-type cells, MCF-7/Adr cells were resistant towards the growth-arresting properties of RO 31 8220 and UCN-01, with resistance ratios of 12.6 and 7.0 respectively. This resistance could be substantially reduced by inclusion of the P-gp inhibitor reserpine. The ratios for GF 109203X, staurosporine and CGP 41251 were 1.2, 2.0 and 2.9 respectively, and they were hardly affected by reserpine. These results suggest that RO 31 8220 and UCN-01 are avidly transported by P-gp but that the other compounds are not. Staurosporine and CGP 41251 at 10 and 20 nm, respectively, decreased efflux of the P-gp probe rhodamine 123 (R123) from MCF-7/Adr cells, whereas RO 31 8220 and GF 109203X at 640 nm were inactive. CGP 41251 was the most effective and GF 109203X the least effective inhibitor of equilibrium binding of [3H]vinblastine to its specific binding sites, probably P-gp, in MCF-7/Adr cells. Overall, the results imply that for this class of compound the structural properties that determine susceptibility towards P-gp-mediated substrate transport are complex. Comparison with ability to inhibit PKC suggests that the kinase inhibitors affect P-gp directly and not via inhibition of PKC. Among these compounds CGP 41251 was a very potent MDR-reversing agent with high affinity for P-gp and least affected by P-gp-mediated resistance, rendering it an attractive drug candidate for clinical development.
Recent advances in the understanding of cellular signal transduction pathways have led to the discovery of potent inhibitors of protein kinases with cytostatic and chemosensitising properties (Powis, 1992) . Prominent among these molecules is the indolocarbazole alkaloid staurosporine (Figure 1 ), a natural product first isolated from Streptomyces staurosporeus (Omura et al., 1977) . Staurosporine has been the lead molecule for the synthesis of a variety of novel kinase inhibitors, for example 7-hydroxystaurosporine (UCN-01) and 4'-N-benzoyl staurosporine (CGP 41251), both of which possess anti-cancer activity in rodents (Akinaga et al., 1991; Meyer et al., 1989) (Figure 1 ). Replacement of the indolocarbazole structure with the related bisindolylmaleimide system (Figure 1 ) furnished a series of staurosporine cogeners exemplified by RO 31 8220 (Davis et al., 1992) and GF 109203X (Toullec et al., 1991) . A feature shared by UCN-01, CGP 41251, RO 31 8220 and GF 109203X is that they inhibit protein kinase C (PKC) selectively, whereas the parent staurosporine molecule inhibits a variety of kinases indiscriminately. Staurosporine (Sato et al., 1990; Sampson et al., 1993) and CGP 41251 (Utz et al., 1994) have been shown to sensitise cells with P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) to cytotoxic agents. Therefore this type of kinase inhibitor might be attractive as a chemotherapeutic agent because of its MDR-reversing activity in combination with cytostatic properties. UCN-01 and CGP 41251 are currently in preparation for phase I clinical evaluation as anti-cancer drugs.
The mechanisms by which staurosporine and its analogues mediate their cytostatic and MDR reversing effects are unclear. It is conceivable that strong, but non-selective, kinase-inhibitory potency is a major determinant of activity exerted by this type of agent. Alternatively high selectivity for PKC, albeit coupled with weaker inhibitory potency, might be required for optimal pharmacological efficacy. It is also possible that cytostasis and MDR reversal are mediated by mechanisms unrelated to kinase inhibition. We reported recently that RO 31 8220 and GF 109203X are much less potent inhibitors of the growth of A549 and MCF-7 cells than staurosporine, UCN-01 and CGP 41251, whereas all five compounds were strong inhibitors of the PKC contained in these cells, with IC50 values of below 100 nM (Courage et al., 1995) . In the present study these five compounds are compared as modifiers of P-gp-mediated MDR. Their abilities to modulate the following three properties involving P-gp were investigated in the human breast cancer-derived multidrug-resistant MCF-7/Adr cell line: (1) growth of these cells in contrast to that of their wild-type counterparts; (2) binding of [3H]vinblastine to P-gp; and (3) cellular accumulation and efflux of rhodamine 123 (R123) and [3H]vinblastine. R123 has been shown to be a suitable fluorescent probe for P-gp-mediated transport (Neyfakh, 1988; Efferth et al., 1989; Hofmann et al., 1992) . The overall objective of the work was to explore the mechanisms of cytostasis and resistance reversal caused by kinase inhibitors in a MDR cell line, with the ultimate aim to assess the potential use of such compounds in cancer therapy.
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Modulation of growth inhibition by reserpine
Reserpine is an effective modifier of P-gp-mediated cytotoxic drug resistance (Pearce et al., 1989) . In order to establish the role of P-gp in the resistance of MCF-7/Adr cells towards the staurosporine analogues, cells were grown in the presence of analogue and reserpine. In preliminary experiments reserpine (5 gLM) was found to increase the sensitivity towards doxorubicin 14.3-fold. (Figure 2 ). These two subpopulations differ in P-gp expression in that the cells with low R123 fluorescence possess more P-gp activity than those which display high dye (Davies et al., 1996) . Figure 2 (Hofmann et al., 1992 , 1995) , but it has to be stressed that their identity is under discussion and they may include sites other than P-gp.
Discussion
The results outlined above highlight considerable differences in cytostatic and MDR reversing ability between kinase inhibitors of the staurosporine type. In Table III , 1995) . The resistance observed in MCF-7/Adr cells against the growth-inhibitory properties of RO 31 8220 and UCN-01 is probably mediated by P-gp. This inference can be drawn from the fact that sensitivity of the cells to the two drugs was partially but significantly restored by inclusion of the P-gp inhibitor reserpine into the cellular incubate. That reserpine was unable to reverse resistance fully indicates that it might have a similar binding affinity for P-gp as RO 31 8220 and UCN-01. Alternatively, 5 gM reserpine might have been insufficient to reverse resistance completely. Of the analogues studied, staurosporine and CGP 41251 were the most potent modulators of cellular R123 efflux and of vinblastine binding. However, their cytostatic potential was affected only a little by the presence of P-gp in the resistant cells. These results suggest that, even although both agents have a high binding affinity for P-gp, they are inefficiently transported by it. In contrast, UCN-01 is probably efficiently transported by P-gp as borne out by the resistance of MCF-7/Adr cells to it. Yet UCN-01 has a low binding affinity for P-gp, allowing reserpine to compete effectively for binding to P-gp and to increase its cytotoxic potential in MCF-7/Adr cells. RO 31 8220 displayed properties similar to those of UCN-01, except that it was transported even more efficiently by Pgp than UCN-01 as adjudged by the strong resistance which MCF-7/Adr cells displayed against it. GF 109203X was neither subject to P-gp-mediated resistance nor able to influence R123 efflux. It was also the weakest inhibitor of [3H]vinblastine binding to P-gp among this series of compounds. Therefore GF 109203X seems to lack affinity for P-gp and susceptibility for transport by P-gp. Interestingly, GF 109203X has recently been shown to be an efficient modulator of drug resistance mediated via the MDR-related protein (Gekeler et al., 1995) . One of the conclusions which can be drawn from the differences between these compounds (see Table III ) is that the MDR-reversing ability of staurosporine analogues appears to be linked to the indolocarbazole structure. Consistent with this conclusion are the results of a preliminary study in which the abilities of CGP 41251 and RO 31 8220 to sensitise MCF-7/Adr cells against doxorubicin were compared. The former at 80 nM increased the sensitivity of cells towards doxorubicin by a factor of 2, but the latter at 2 gM had no effect (J Budworth and A Gescher, unpublished) .
How can the differences between the compounds in cytostatic potency and susceptibility towards the effect of reserpine be integrated with those of the short-term assays of R123 accumulation and efflux and [3H]vinblastine binding (Table III) ? Of the five compounds investigated, CGP 41251 has the highest affinity to the vinblastine binding site and is hardly subject to resistance or modulation by reserpine. In the light of the high affinity of CGP 41251 for P-gp, these findings may reflect its long dwell time on its P-gp binding site, suggesting that the pump transports the drug slowly. For GF 109203X occupancy of P-gp is likely to be low because of its low affinity. UCN-01 and RO 31 8220, inhibitors with medium affinity for P-gp, can occupy the pump and turnover is high. RO 31 8220 was the most inconsistent of the five molecules in that it did not modulate R123 efflux or [3H]vinblastine accumulation, yet was subject to P-gpmediated resistance. The reasons for the observed differences are undoubtedly complex. One variable which has not been considered in the interpretation outlined above is the possible effect of these kinase inhibitors on mdrl mRNA levels. Transcription of the mdrl gene is stimulated through a c-raf kinase pathway, which operates downstream from ras (Cornwall and Smith, 1993) . Staurosporine has recently been reported to decrease mdrl expression (Bhat et al., 1994; L McKinley and TW Gant, unpublished) . Thus we cannot exclude the possibility that the differences in growthinhibitory properties between MCF-7 and MCF-7/Adr cells described above are a consequence of altered mdrl expression, perhaps via kinase inhibition. Alternatively, in the growth inhibition experiments described above, blockade of P-gp at sub-growth inhibitory concentrations may have elicited accumulation of an endogenous P-gp substrate that in turn increased P-gp expression, thus attenuating the effects of the compounds via a feedback mechanism. These possibilities are currently under investigation.
One of the aims of this study was to probe for the link between PKC inhibition and ability to inhibit P-gp. There seems to be a close functional association between MDR and PKC (O'Brian et al., 1989; Chambers et al., 1990) , but the mechanisms involved are unclear. Here we describe staurosporine as a potent growth inhibitor of MCF-7/Adr cells and a good MDR-reversing agent. Staurosporine is one of the most effective PKC inhibitors thus far discovered (Tamaoki and Nakano, 1990) , but arguably the least selective of the five agents under investigation here. The PKC-specific staurosporine cogeners used in this study share similar PKC-inhibitory potency (Courage et al., 1995 ). Yet the results described above suggest that these staurosporine analogues differ dramatically in both ability to reverse P-gpmediated drug resistance and susceptibility towards transport by P-gp. This discrepancy suggests that inhibition of total 1068 PKC activity by these compounds is not a major mechanism by which they modulate P-gp transport. A similar inference has been drawn previously for staurosporine in other cell types (Miyamato et al., 1993; Wasukawa et al., 1993) .
In conclusion, the results presented here indicate that selectivity for PKC is probably not a prerequisite for a staurosporine analogue to possess MDR reversing properties in cells which overexpress P-gp. These molecules differ substantially in ability to bind to and to be transported by P-gp. Among the five kinase inhibitors investigated the indolocarbazoles CGP 412521 and staurosporine have the highest affinity for P-gp but are transported only slowly. Thus they possess the most suitable properties as MDRreversing agents. Of the two compounds, CGP 41251 is the more attractive drug candidate for potential clinical use, because it lacks the toxicity associated with staurosporine (Meyer et al., 1989) . Abbreviations BSA, bovine serum albumin; FCS, fetal calf serum; IC5,0 concentration which inhibits growth by 50%; MDR, multidrug resistance; P-gp, P-glycoprotein; PKC, protein kinase C; PMSF, phenylmethylsulphonyl fluoride; R123, rhodamine 123
